Mitokine Bioscience, LLC is developing a critical new treatment for diabetes. Mitokines business and market approach is to find and make available to the medical community new solutions to the treatment of chronic disease that build upon natural processes. Mitokine intends to follow this effort with a larger canine study to meet the requirements for FDA approval of a veterinary product and develop a similar treatment for human diabetes. Current research at Mitokine is centered on the development of a critical new treatment for diabetes. This treatment restores an amino acid that is normally synthesized, along with insulin, in pancreatic beta cells. In diabetes, beta cell distruction depletes both products.
